Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed localized adenocarcinoma of the prostate
• Candidate for prostatectomy
• PATIENT CHARACTERISTICS:
• Age:
• 21 and over
• Performance status:
• Not specified
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 4,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.4 mg/dL
• AST no greater than 3 times normal
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Calcium no greater than 10.2 mg/dL
• No idiopathic urinary calcium stone disease
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• Not specified
• Endocrine therapy:
• No prior hormonal therapy for prostate cancer
• No concurrent hormonal therapy, including luteinizing hormone-releasing hormone agonists, antiandrogens, glucocorticoids, ketoconazole, finasteride, diethylstilbestrol, or progestins
• Radiotherapy:
• No prior brachytherapy or external beam radiotherapy for prostate cancer
• Surgery:
• See Disease Characteristics
• Other:
• At least 7 days since prior vitamin D therapy or calcium supplements
• No other concurrent vitamin D analogues or calcium supplements
• No concurrent magnesium-containing antacids
• No concurrent thiazide-containing diuretics
• No concurrent phenytoin, phenobarbital, glutethimide, digoxin, or digitalis